KRAS and colorectal carcinoma: On the other hand, in the recently presented KRYSTAL-1 study (NCT03785249), a multicenter phase I/II study of MRTX849 in patients with advanced solid tumors that harbor a KRAS G12C mutation, 3 out of 18 evaluable patients had a confirmed PR, with a DCR observed in 94% of CRC patients [54].